Leap Therapeutics Rebrands and Acquires Zcash Tokens

Tip Ranks
2025.11.12 13:33
portai
I'm PortAI, I can summarize articles.

Leap Therapeutics, now Cypherpunk Technologies Inc., announced a rebranding and a digital asset treasury strategy, acquiring 203,775 Zcash tokens for $50 million. The company appointed Khing Oei and William McEvoy to its board, with McEvoy as Chief Investment Officer. The Nasdaq ticker symbol will change to ‘CYPH’ on November 13, 2025. Analysts rate LPTX stock as a Hold with a $1.25 price target, while TipRanks’ AI Analyst suggests it is an Underperform due to financial challenges and bearish trends.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Leap Therapeutics ( (LPTX) ) just unveiled an update.

On November 11, 2025, Cypherpunk Technologies Inc. announced a series of strategic changes, including a rebranding from Leap Therapeutics and the introduction of a digital asset treasury strategy. The company has used $50 million from a private placement led by Winklevoss Capital to acquire 203,775 Zcash tokens, aiming to enhance shareholder value through this investment. Additionally, Khing Oei and William McEvoy were appointed to the board, with McEvoy also serving as Chief Investment Officer, marking a significant leadership expansion. The company also announced a change in its Nasdaq ticker symbol to ‘CYPH’ effective November 13, 2025, reflecting its new strategic direction.

The most recent analyst rating on (LPTX) stock is a Hold with a $1.25 price target. To see the full list of analyst forecasts on Leap Therapeutics stock, see the LPTX Stock Forecast page.

Spark’s Take on LPTX Stock

According to Spark, TipRanks’ AI Analyst, LPTX is a Underperform.

Leap Therapeutics faces significant financial challenges with persistent losses and no revenue growth, resulting in a low financial performance score. The technical analysis suggests bearish trends with some potential for short-term volatility. The company’s valuation metrics are also unfavorable due to negative earnings. No recent earnings call or corporate events data are available to impact the score further.

To see Spark’s full report on LPTX stock, click here.

More about Leap Therapeutics

Cypherpunk Technologies Inc., formerly known as Leap Therapeutics, Inc., operates in the digital asset and biotechnology sectors. The company focuses on developing novel therapies for cancer patients and has recently implemented a digital asset treasury strategy centered on Zcash, a privacy-focused cryptocurrency.

Average Trading Volume: 3,541,541

Technical Sentiment Signal: Sell

Current Market Cap: $26.03M

For a thorough assessment of LPTX stock, go to TipRanks’ Stock Analysis page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.